LARVOL announces the launch of CLIN, an easy-to-navigate platform that curates ten years of historical clinical trial data, with an initial focus on immuno-oncology. CLIN was recently used to extract and analyze data for LARVOL’s poster presentation at the 2021 Virtual Meeting of the American Society of Clinical Oncologists (ASCO).
San Francisco, CA (June 8, 2021) – BUSINESS WIRE – LARVOL, the leading provider of data and intelligence solutions for oncologists and the pharmaceutical and biotech industries, today announced the launch of CLIN, an easy-to-navigate platform that curates ten years of historical clinical trial data, with an initial focus on immuno-oncology.
Researchers, Medical Science Liaisons (MSLs), and oncologists can now access a complete database of more than 5,000 clinical trials and 20,000 documents, manually reviewed by experts, and coded to extract every table, graph, and figure. This SaaS platform allows cancer researchers and drug developers to search and analyze data across all clinical trials within a specific cancer type.
Additional benefits include:
Faster Curation: LARVOL’s team of experts manually review new trial data with speed and precision, posting results and exhibits in less than 24 hours so data is available in hours, not days. New data is added as it's released from publications, conferences, and guidelines.
Easier Searching: Detailed meta-tags make it easy to search, filter, and browse trial data by tumor type, drug, phase, endpoint, or even medical conference. The result is the most up-to-date repository of available oncology trial data available.
More Customizable: The user-friendly platform makes it easy to compare and extract historical data and customize per the user’s requirements with composite KM Curves and customizable forest plots.
“The future of improved cancer treatments lies, in part, in the ability to more quickly curate research and insights to provide researchers with access to the complete universe of clinical trial data. CLIN does just that,” said Bruno Larvol, CEO and Founder of LARVOL. “CLIN is an exciting next step in the innovative work LARVOL is doing to streamline the work of oncologists and researchers.”
CLIN was recently used to extract and analyze data for LARVOL’s poster presentation at the 2021 Virtual Meeting of the American Society of Clinical Oncologists (ASCO). The poster, titled “Control arm heterogeneity in trials for unselected advanced triple-negative breast cancer,” explored the application of CLIN in assessing heterogeneity in control arm time-to-event outcomes.
LARVOL supports the data and intelligence needs of the pharmaceutical and biotech industries with expert curated information. Their products include competitive intelligence, KOL monitoring, and social listening tools along with predictive cancer biomarker and clinical trial databases. LARVOL curates data using a proven combination of broad therapeutic-area expertise and proprietary natural language processing technology to keep their customers at the forefront of the industry. The VR-first, remote-always LARVOL team includes MDs, PhDs, and industry professionals around the globe who curate data from over 25,000 sources oncologist and and distill the most relevant information into concise reports that provide real-time insights and time-saving analysis.
In this edition of our ongoing series "In The Spotlight", we're excited to chat with Linh Nguyen, the VP Sales at LARVOL. With a passion for healthcare and a commitment to making a difference in the oncology field, Linh has been a vital part of our team for over six years. Let’s get to know Linh better through her own words, exploring her journey, motivations, and the personal interests that round out her life.
In 2020, as most of the business world wrestled with the transition to remote work, my company chose an alternate approach. As Founder and CEO, I began pushing for a very different but equally culture-shifting change. I moved our corporate headquarters to the metaverse, and we’re never looking back.
The battle against cancer is shifting, with Antibody-Drug Conjugates (ADCs) leading a revolution in precision therapy. These biological innovators are changing the game for many patients, offering a glimmer of hope in an often daunting prognosis. Here’s a closer look at the promising world of ADCs and how they're transforming cancer care.
Navigating the busy world of pharmaceutical conferences can be a daunting task, filled with endless sessions, abstracts, and updates to keep track of. This is where LARVOL CONF comes into play – offering a simple, yet powerful way to organize and manage conference information effectively.